Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Neil E Fleshner
Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance.
J Urol. 2017 Dec 12;:
Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis.
Can Urol Assoc J. 2018 Feb 23;:
Clin Cancer Res. 2017 May 01;23(9):2169-2176
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Urol Oncol. 2018 Feb 14;:
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.
Bladder Cancer. 2018 Jan 20;4(1):91-112
Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.
Can Urol Assoc J. 2018 Feb 06;:
Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis.
Clin Genitourin Cancer. 2018 Jan 05;:
Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance.
Prostate Cancer Prostatic Dis. 2017 Dec 14;:
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
J Clin Oncol. 2017 Dec 13;:JCO2017741173
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto